Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Van ECK Associates Corp

Van ECK Associates Corp lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2,567.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 352,217 shares of the medical research company's stock after purchasing an additional 339,013 shares during the period. Van ECK Associates Corp owned about 0.09% of Thermo Fisher Scientific worth $186,954,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Linden Thomas Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 8.8% during the third quarter. Linden Thomas Advisory Services LLC now owns 1,546 shares of the medical research company's stock worth $783,000 after buying an additional 125 shares during the last quarter. Avestar Capital LLC boosted its holdings in Thermo Fisher Scientific by 15.6% in the 3rd quarter. Avestar Capital LLC now owns 1,135 shares of the medical research company's stock valued at $575,000 after purchasing an additional 153 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Thermo Fisher Scientific by 17.7% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,241 shares of the medical research company's stock valued at $628,000 after purchasing an additional 187 shares in the last quarter. Steward Financial Group LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter valued at approximately $73,000. Finally, Commonwealth Equity Services LLC lifted its position in shares of Thermo Fisher Scientific by 0.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 99,703 shares of the medical research company's stock valued at $50,467,000 after acquiring an additional 835 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on TMO shares. HSBC lifted their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a "buy" rating in a research report on Wednesday, April 17th. Sanford C. Bernstein restated a "market perform" rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Raymond James boosted their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an "outperform" rating in a report on Thursday, February 1st. The Goldman Sachs Group boosted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a report on Wednesday, April 10th. Finally, Citigroup assumed coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a "neutral" rating and a $620.00 price target for the company. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $606.76.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold 52,277 shares of company stock worth $29,649,264 in the last quarter. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.6 %

Thermo Fisher Scientific stock traded up $3.27 during trading on Monday, reaching $576.87. 962,347 shares of the company's stock were exchanged, compared to its average volume of 1,554,585. The company's 50-day moving average is $573.60 and its two-hundred day moving average is $530.40. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The firm has a market cap of $220.20 billion, a price-to-earnings ratio of 36.82, a PEG ratio of 2.41 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts' consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion during the quarter, compared to analysts' expectations of $10.14 billion. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's payout ratio is currently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.